

Enhanced Functional Recovery in MRL/MpJ Mice after Spinal Cord Dorsal Hemisection

Sandrine Thuret^{1,2,3*}, Michaela Thallmair^{2,b}, Laura L. Horky^{2,c}, Fred H. Gage^{1*}

Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, California, United States of America

Abstract

Adult MRL/MpJ mice have been shown to possess unique regeneration capabilities. They are able to heal an ear-punched hole or an injured heart with normal tissue architecture and without scar formation. Here we present functional and histological evidence for enhanced recovery following spinal cord injury (SCI) in MRL/MpJ mice. A control group (C57BL/6 mice) and MRL/MpJ mice underwent a dorsal hemisection at T9 (thoracic vertebra 9). Our data show that MRL/MpJ mice recovered motor function significantly faster and more completely. We observed enhanced regeneration of the corticospinal tract (CST). Furthermore, we observed a reduced astrocytic response and fewer micro-cavities at the injury site, which appear to create a more growth-permissive environment for the injured axons. Our data suggest that the reduced astrocytic response is in part due to a lower lesion-induced increase of cell proliferation post-SCI, and a reduced astrocytic differentiation of the proliferating cells. Interestingly, we also found an increased number of proliferating microglia, which could be involved in the MRL/MpJ spinal cord repair mechanisms. Finally, to evaluate the molecular basis of faster spinal cord repair, we examined the difference in gene expression changes in MRL/MpJ and C57BL/6 mice after SCI. Our microarray data support our histological findings and reveal a transcriptional profile associated with a more efficient spinal cord repair in MRL/MpJ mice.

Citation: Thuret S, Thallmair M, Horky LL, Gage FH (2012) Enhanced Functional Recovery in MRL/MpJ Mice after Spinal Cord Dorsal Hemisection. PLoS ONE 7(2): e30904. doi:10.1371/journal.pone.0030904

Editor: Brian D. McCabe, Columbia University, United States of America

Received: October 19, 2011; **Accepted:** December 29, 2011; **Published:** February 13, 2012

Copyright: © 2012 Thuret et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: ST was supported by the Paralyzed Veterans of America Spinal Cord Research Foundation (www.pva.org) and the Paralysis Project of America (www.paralysisproject.org). MT was supported by the Deutsche Forschungsgemeinschaft (www.dfg.de/). Additional support was provided by the Christopher and Dana Reeve Foundation (www.christopherreeve.org). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: sandrine.1.thuret@kcl.ac.uk (ST); gage@salk.edu (FHG)

^{1a} Current address: Institute of Psychiatry, King's College London, London, United Kingdom

^{2b} Current address: Brain Research Institute, ETH and University Zurich, Zurich, Switzerland

^{2c} Current address: Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts, United States of America

Introduction

Injury to the mammalian spinal cord typically results in very limited regeneration of damaged axons, causing permanent functional deficits [1]. Central nervous system (CNS) axonal regeneration appears to be impeded partly by myelin inhibitors [2] and by formation of a post-lesion scar barrier [3]. However, if axons can traverse the injury site, there is evidence that they may re-grow into unscarred regions [4,5].

The main components of the scar are gliotic astrocytes and microglia/macrophages [6]. Upon injury, astrocytes proliferate, up-regulate the expression of glial fibrillary acidic protein (GFAP) and form a dense network of glial processes at the injury site. In addition to creating this physical barrier, astrocytic gliosis will result in the production of a variety of cytokines, cell adhesion and extra-cellular matrix molecules. Some of these molecules, such as chondroitin sulfate proteoglycans (CSPG), have been shown to inhibit axonal growth [7] and, if degraded in the glial scar at the injury site, axonal regeneration as well as functional recovery is promoted [8]. Similarly, suppression of glial scar formation with a 2-Gy dose of radiation after SCI improves functional recovery [9].

Wound healing of mammalian tissue is a long process and is always accompanied by scarring. In general, adult mammals are poor healers compared to lower vertebrates such as some tailed amphibians, which can completely regenerate their spinal cord without scar formation [10]. Among mammals, the MRL/MpJ mouse strain has a unique capacity for wound healing and regeneration, as shown by the closure of ear punches with normal tissue architecture and cartilage replacement. This characteristic is in contrast to the C57BL/6 mouse, which heals only part of the ear punch hole and forms a scar [11]. Furthermore, the MRL/MpJ mouse has been shown to regenerate injured heart tissue in contrast to the C57BL/6 mouse [12]. Neither of these regenerative repair processes is normally seen in adult mice, and the healing response of MRL/MpJ mice is reminiscent of amphibian regeneration with scarless healing [11,12]. More recently, Chadwick and colleagues [13] showed that, after amputation, MRL mouse digit tips were found to distally re-grow more quickly and reform nails either partially or completely to a greater degree than C57BL/6 mice. Gourevitch and colleagues [14] further observed a blastema-like structure along apparent chondrogenesis, consistent with a histological profile of a regenerative response to injury.

Because the MRL/MpJ mouse has shown enhanced healing abilities without scarring, we investigated whether injured MRL/MpJ spinal cord would show enhanced healing and possibly axon regeneration without glial scar formation. To assess putative regenerative repair in the MRL/MpJ spinal cord, we performed a dorsal spinal cord hemisection and used C57BL/6 mice as control animals.

Materials and Methods

Animals

The MRL/MpJ is an inbred mouse derived from the interbreeding of 4 progenitor inbred lines: LG/J (75%), AKR/J (12.6%), C3H/HeJ (12.1%) and C57BL/6 (0.3%) [15]. Over 20 genetic loci have been identified and their healing phenotype is a complex multigenic and sexually dimorphic trait [16,17,18,19].

We chose C57BL/6 animals as controls because they have been used as a control strain in all published work related to the enhanced healing abilities of MRL/MpJ mice, including all gene and loci identification studies [16,17,18,19,20,21]. Using the C57BL/6 mice as a control strain thereby allows us to compare our gene expression data to already published literature. The intact C57BL/6 mice performed better than the MRL/MpJ animals in the rotarod and the grid test. Therefore, the motor recovery results were analyzed after normalizing the performance of the injured MRL/MpJ and C57BL/6 mice to their respective baseline levels (intact mice). It is likely that the MRL/MpJ mice are not as agile as the C57BL/6 mice because of their higher body weight (10-week-old female C57BL/6 weighed $20.1 \text{ g} \pm 0.5 \text{ g}$, MRL/MpJ weighed an average of $31.7 \text{ g} \pm 0.4 \text{ g}$). The only available inbred strains of mice matching the weight of MRL/MpJ mice, the C3HeB/FeJ strain, is blind (Mouse Phenome Database, <http://www.jax.org>) and therefore would not have been suitable for behavioral testing.

Ten-week-old female MRL/MpJ and C57BL/6 mice were purchased from the Jackson Laboratory, ME. They were housed in groups of 5 or singly (after SCI) and had access to water and food ad libitum at the Salk Institute animal facilities. All animal procedures were in accordance with NIH guidelines and approved by the Salk Institutional Animal Care and Use Committee. Intraperitoneal injections of ketamine (100 mg/kg) and xylazine (10 mg/kg) were used as anesthesia for all surgical procedures and before perfusion.

SCI and post-operative care

Under appropriate aseptic techniques, 10-week-old female mice (22 MRL/MpJ and 22 C57BL/6) received a partial dorsal laminectomy at a single thoracic vertebral segment (T9). The spinal cord was exposed and Lidocaine (2%, 10 μl , Bimeda, Riverside, MO) was applied to the dura for 1 minute to anesthetize the region to be transected. The dorsal half of the spinal cord was cut 0.5 mm deep with a pair of microscissors to sever the main parts of the CST, including the dorsal lateral component of the CST (the diameter of the spinal cord at T9 was not significantly different between the two strains, allowing injuries of equal sizes for both strains). The overlying muscle layers were sutured and the skin was stapled closed. Postoperatively, all animals were placed singly in a cage on warming pads and were provided with moist food pellets on the bottom of the cage. Temperature and respiration were monitored until animals were fully awake. Then cages were placed back on the housing system rack. Bladders were manually expressed twice a day until normal voiding reflexes returned. An antibiotic (enrofloxacin, 2.27 mg/kg, Baytril, Bayer, KS) was given once daily for 6 days. Animals were

transcardially perfused with saline, followed by 4% paraformaldehyde at different time points post-SCI.

Behavioral analyses

Intact MRL/MpJ and C57BL/6 mice ($n = 10$ in each group) were used to establish the baseline performance of each strain in the rotarod, grid and footprint test (baseline group). Also, injured groups of 10 MRL/MpJ and 10 C57BL/6 mice were tested 4 days before the injury and up to 88 days after the injury.

Rotarod test. The Rotamex 4/9 (Columbus Instrument, OH) was used to evaluate fore-and hindlimb motor coordination and balance. Each mouse was placed on the slowly moving rotarod (5 rpm) and the trial was started when the animal found its balance. The rotarod accelerated from 5 rpm to a maximum of 70 rpm within 3 minutes. The latency to fall off the rotarod was recorded. Mice underwent 3 consecutive trials. The mean latency for 3 trials was used for statistical analysis.

Grid test. This test evaluated the ability of the mice to navigate over a wire mesh grid (2.5 \times 2.5 cm grid spaces, 28 \times 35 cm total area). Each mouse was videotaped while on the grid until it achieved a total of 20 steps. A foot-fault was scored each time the animal misplaced its hindlimb to protrude entirely or partially through the grid.

Bladder function. The bladder of each injured animal was voided twice daily until it recovered autonomic bladder function. The amount of urine voided (or the level of "bladder fullness") was estimated and ranked from 3 to 0: 3 = dysfunctional; full bladder, medium to high pressure needed to manually express it and a large amount of urine expressed, 2 = medium amount of urine expressed after medium pressure, 1 = small amount of urine expressed after slight pressure, and 0 = empty bladder and no urine expressed.

CST tracing

Six MRL/MpJ and 6 C57BL/6 received bilateral CST tracing at 40 days post-injury (dpi), 10 MRL/MpJ and 10 C57BL/6 at 95 dpi, and 2 intact MRL/MpJ and 2 intact C57BL/6 also received bilateral CST tracing. A hole was drilled on each side of the skull overlying the sensorimotor cortex. The anterograde neuronal tracer biotin dextran amine (BDA) (10% BDA in 0.01 M phosphate buffer, pH 7.4; Molecular Probes, Eugene, OR) was injected (2 μl) at 4 injection sites into the sensorimotor area (anterior-posterior coordinates from bregma in mm: 1.0/1.5, 0.5/1.5, -0.5/1.5, -1.0/1.5, at a depth of 0.5 mm) using a Hamilton syringe. Two weeks after BDA injection, the animals were perfused and tissue was collected for histology.

BrdU injections

Bromodeoxyuridine (BrdU; Sigma) was dissolved in 0.9% NaCl and filtered at 0.2 μm . To label dividing cells in intact mice, 12 animals received a daily intraperitoneal injection for 6 consecutive days at a dose of 50 mg/kg body weight (10 mg/ml BrdU). Six mice were sacrificed 1 day and 6 mice were sacrificed 4 weeks after the last injection to assess rate of proliferation, differentiation and survival of mitotic cells. SCI mice received the first injection 2 hours after the injury. Six lesioned mice received a single injection 2 hours after injury and were sacrificed 1 day later. Twenty injured mice received one injection per day for 6 days. Of these, 10 animals were sacrificed at 54 dpi and 10 were sacrificed at 109 dpi.

Tissue processing

Spinal cords were cut into 7-mm segments and embedded in cryomolds (Fisher Scientific, Pittsburgh, PA) with O.C.T.

mounting medium (Tissue Tek, Torrance, CA). Mounted spinal cord segments were stored at -80°C until processed further. Spinal cords were sectioned sagittally on a cryostat at $20\ \mu\text{m}$ thickness and stored on slides at -20°C .

CST detection and analysis

The spinal cord sections were incubated with an avidin–biotin–peroxidase complex (ABC Elite, Vector Laboratories, Burlingame, CA), and the BDA tracer was visualized by a nickel-enhanced diaminobenzidine (DAB) reaction [22]. BDA-labeled fibers were quantified at 0.5 mm and 2 mm caudal and at 5 mm rostral to the lesion site. To account for inter-individual tracing variability, numbers were normalized to the amount of fibers 5 mm rostral to the lesion site, where the CST was intact, and are presented as percentages [8].

BrdU immunohistochemistry and quantification

For the stereological quantification of BrdU-labeled cells, cryostat sections were stained with rat anti-BrdU primary antibody (1:100; Accurate Chemicals) for DAB immunohistochemistry. BrdU-labeled cells in intact mice were quantified as described before [23]. To obtain the number of BrdU-labeled cells per mm^3 in injured spinal cords, labeled cells were counted at the injury epicenter, every $60\ \mu\text{m}$ through the entire width of the spinal cord. For each sagittal section, the area surrounding the injury epicenter (5 mm surrounding the injury epicenter) was traced and recorded using a mechanical stage attached to an Olympus BH2 microscope, a Dage MTI CCD-300TIFG Video camera (Michigan City, IN) and the StereoInvestigator software (MicroBrightfield, Colchester, VT). The number of labeled cells within each traced area was recorded.

Multiple marker immunofluorescence and quantification

Sections were processed for multiple markers to determine the phenotype of BrdU-labeled cells. Primary antibodies detecting immature and mature astrocytes (S-100 β polypeptide), mature astrocytes (GFAP), oligodendrocyte progenitors (NG2), microglia (OX-42), and immature (TUJ1) and mature neurons [neuronal nuclear antigen clone A60 (NeuN)] were used. Cryostat sections were pretreated for BrdU detection as described previously [23]. Three compatible primary antibodies were incubated on the sections for 2 days at 4°C in TBS +0.1% Triton X-100 +5% donkey serum. Primary antibodies were used at the following concentrations: rat anti-BrdU (1:100; Accurate Chemicals), rabbit anti-S-100 β (1:10,000; SWant, Bellinzona, Switzerland), mouse anti-NeuN (1:10; clone A60; Dr. R. Mullin, Salt Lake City, UT), rabbit anti-GFAP (1:1000; Dako, Carpinteria, CA), rabbit anti-NG2 (1:500; Chemicon, Temecula, CA) and mouse anti-OX-42 (1:200; Serotec, UK). Sections were rinsed twice in 0.1 M TBS, pH 7.5, and blocked in 0.1 M TBS +0.1% Triton X-100 for 15 min before application of secondary antibodies. The following secondary antibodies were applied in 0.1 M TBS and 0.1% Triton X-100, each at a concentration of 1:250 for 2 hr in the dark: donkey anti-rat IgG conjugated to FITC (1:250; Jackson ImmunoResearch, West Grove, PA), donkey anti-mouse conjugated to Cy2 or Cy5 (1:250; Jackson ImmunoResearch), and donkey anti-rabbit conjugated to Cy2 or Cy5 (1:250; Jackson ImmunoResearch). Incubation with secondary antibodies was followed by three rinses (15 min) in TBS. Slides were then immediately coverslipped using polyvinyl alcohol-1,4 diazabicyclo[2.2.2]octane and kept in the dark at 4°C until analysis.

Multiple label immunofluorescent images were collected and quantified using confocal microscopy (Bio-Rad MRC 1000, Hercules, CA). Single confocal plane images of BrdU or

phenotype markers (see above) were collected and combined to assess co-localization. A cell was scored for double-staining when a well-defined BrdU-labeled nucleus was associated with an immunopositive (e.g., GFAP, S100b etc.) cell body. The entire cell was followed through the z -axis, and only cells with a well-circumscribed, immunopositive soma were considered positive for a particular phenotype. A total of 100 BrdU cells were randomly counted at the injury epicenter.

TdT-mediated dUTP nick end labelling (TUNEL) assay

Apoptosis was examined by TUNEL assay, using a commercially available kit (Oncor, Apoptag). The modified protocol developed by Whiteside et al. was followed to simultaneously counterstain with Hoechst 33342 [24]. TUNEL positive cells were only counted as apoptotic cells if the nucleus had fragmented into several membrane-bounded, highly condensed bodies and if it exhibited shrinkage of both cytoplasm and nucleus, creating pericellular space. Any artifacts of TUNEL labeling, i.e., non-nuclear material, was disregarded.

Detection and quantification of micro-cavities

The sections were counterstained with GFAP antibody (rabbit anti-GFAP, 1:1000; Dako). To obtain the number of micro-cavities per mm^3 , micro-cavities were counted at the injury epicenter, every $60\ \mu\text{m}$ through the entire width of the spinal cord. For each section the area surrounding the injury epicenter was traced and recorded as described above. The number of micro-cavities within the traced area was recorded.

Statistical evaluation

All the behavioral data and quantification of traced CST fibers were analyzed using a two-factor ANOVA. Post hoc analysis was carried out using Bonferroni-corrected individual comparisons (Microsoft Excel and XLSTAT; Addinsoft, NY). Statistical evaluation of bladder recovery was assessed by a non-parametric Mann Whitney test. Statistical evaluation of BrdU cell counts and micro-cavity quantification was performed using a Student's t -test. In all analyses, a P-value of less than 0.05 was chosen as significance threshold. All data are presented as the mean \pm standard error of the mean (SEM).

Experimental design for the microarray gene expression analysis

For MRL/MpJ and C57BL/6 mice, three groups were examined at 4 dpi: intact control, laminectomy control and hemisection at T9. For each condition, 3 mice were sacrificed and a 1-cm spinal cord segment containing the injury epicenter was collected.

RNA extraction and microarray procedures

The procedure was performed as described in detail before [25]. Total RNA was extracted from each sample individually using TRIzol reagent (Invitrogen, Carlsbad, CA). First-strand cDNA was generated by using a T7-linked-(dT)₂₄ primer. After second-strand synthesis, the double-stranded cDNA was used for in vitro transcription using the ENZO BioArray High-Yield RNA transcript labeling kit (ENZO, Farmingdale, NY). The labeled cRNA was purified and fragmented. Each fragmented, biotin-labeled cRNA sample (20 μg) was hybridized to an Affymetrix mouse 430A chip. After scanning, array images were assessed by eye to confirm scanner alignment and the absence of significant bubbles or scratches. Chips had to meet the following criteria to be included in the data analysis: the number of probe pairs called

present had to be greater than or equal to 30%, all spiked-in bacterial controls had to be called present, background had to be <200, the number of outliers had to be <500, and the 3V/5V ratio of GAPDH and actin had to be <2.

Microarray data analysis and quantitative PCR validation

The chips were analyzed using two different complementary analytical tools. Data were preprocessed (*.dat files to *.cel files) using Affymetrix Microarray Analysis Suite (MAS) 4.0. Data were subsequently analyzed using the dChip 1.3 PM-MM [26] and the Drop Method [27]. dChip approximates expression values by modeling the whole body of chip data to an ideal system, and Drop determines the significance of change between the triplicate groups statistically with minimal assumptions.

To detect up- or down-regulated genes following SCI, Hemisection chips were compared to Laminectomy control chips for both strains of mice. Each group had 3 chips, so each comparison had a 3×3 design, with a possibility of 9 pairwise comparisons for each group. To obtain a list of genes that were differentially expressed after SCI in MRL/MpJ animals, but not significantly changed in C57BL/6 mice, we compared the gene lists of MRL/MpJ and C57BL/6 mice after imposing very strict criteria (dChip fold change>1.2 AND Drop method confidence = 95%) for the MRL/MpJ chips and very loose criteria (dChip fold change>1.2 OR Drop method confidence = 50%) for the C57BL/6 chips. To detect differentially expressed genes between the 2 uninjured strains, Intact control chips from MRL/MpJ were compared to Intact control chips from C57BL/6. For

statistical significance we imposed dChip fold change>1.2 and Drop method confidence = 95%.

Expression changes of genes of interest were verified by quantitative RT-PCR (Q-PCR). cDNA was prepared from RNA samples used for GeneChip analysis, and reverse transcription was performed using Superscript First-strand cDNA Synthesis System (Invitrogen). Primer Express v1.5 software was used to design oligonucleotide primers (Applied Biosystems, Foster City, CA) (see methods Table S1 for sequences of primers), which were constructed by Sigma-Aldrich. Q-PCR was performed with 3.33 ng of cDNA, SYBR Green Master Mix (Applied Biosystems), and 0.2 μM of each primer in a 25-μl reaction. All reactions were performed in triplicate using an ABI Prism 7700 Sequence Detection System (Applied Biosystems). Data analysis was performed according to the protocol provided by Applied Biosystems using Sequence Detector Systems v1.7 software. Intact spinal cord cDNA was used to create standard curves for both strains. Expression of each gene was calculated based on the standard curve for a given primer set. The relative amount of calculated message was normalized to the level of a control gene (18s rRNA). The Q-PCR results are summarized in table 1

Results

Enhanced functional recovery of MRL/MpJ mice after SCI

The locomotor performance of injured mice was assessed at several time points up to 88 dpi. Due to the disparity in performance between intact MRL/MpJ and C57BL/6 mice, a

Table 1. Fold changes for the 10 most up- and down-regulated genes in MRL/MpJ compare to C57BL/6 mice after spinal cord hemisection.

Up-regulated Genes	MRL/MpJ Fold Change	C57BL/6 Fold Change	Down-regulated Genes	MRL/MpJ Fold Change	C57BL/6 Fold Change
interferon activated gene 202B [GeneID: 26388]	35.66 [48.80]	1.00 [0.98]	Mus musculus adult male olfactory brain cDNA, RIKEN full-length enriched library, clone:6430537M22 product:unknown EST, full insert sequence.	-4.43	-1.82
allograft inflammatory factor 1 [GeneID: 11629]	23.83 [32.15]	3.14 [2.32]	potassium voltage-gated channel, shaker-related subfamily, beta member 1 [GeneID: 16497]	-3.75 [-4.52]	-1.61 [-2.96]
histidine ammonia lyase [GeneID: 15109]	18.4 [15.34]	2.09 [3.43]	calcitonin-related polypeptide, beta [GeneID: 116903]	-3.55 [-4.82]	-1.50 [-1.03]
Mus musculus, clone MGC:28142 IMAGE:3982042, mRNA, complete cds	7.88	2.70	vesicle-associated membrane protein 1 [GeneID: 22317]	-3.41 [-2.98]	-1.34 [-0.63]
cDNA sequence BC032204 [GeneID: 108101]	5.75	1.85	sulfotransferase family 4A, member 1 [GeneID: 29859]	-3.36 [-4.23]	-1.63 [-1.06]
apolipoprotein B editing complex 1 [GeneID: 11810]	4.68 [6.98]	1.68 [1.85]	regulator of G-protein signaling 4 [GeneID: 19736]	-3.16 [-2.98]	-1.35 [-0.85]
cDNA sequence BC032204 [GeneID: 108101]	4.45	1.81	Parvalbumin [GeneID: 19293]	-3.10 [-4.50]	-1.32 [-1.28]
Rho, GDP dissociation inhibitor (GDI) beta [GeneID: 11857]	4.44 [3.96]	1.85 [1.78]	creatine kinase, mitochondrial 1, ubiquitous [GeneID: 12716]	-3.02 [-2.20]	-1.87 [-1.00]
beta-glucuronidase [GeneID: 110006]	4.27 [3.98]	1.63 [1.86]	cartilage acidic protein 1 [GeneID: 72832]	-3.00 [-5.02]	-1.30 [-1.32]
cysteine rich protein 61 [GeneID: 16007]	4.18 [6.40]	1.86 [2.59]	solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 6 [GeneID: 140919]	-2.94 [-1.98]	-1.23 [-0.75]

The complete data set is available at http://genechip.salk.edu/rawdata/Thuret_MRL.zip.

Expression changes of genes of interest were also verified by quantitative RT-PCR (Q-PCR). When applicable, the Q-PCR fold changes are presented in brackets []. doi:10.1371/journal.pone.0030904.t001

control group of intact, age-matched MRL/MpJ and C57BL/6 animals underwent the same behavioral tests as the injured mice to establish the baseline performance for both mice strains.

The rotarod test evaluates fore- and hindlimb motor coordination and balance. Intact mice of both strains improved and reached a plateau at 18 days, showing the same performance up to 88 days (Fig. 1a). However, C57BL/6 mice performed better from the start (72.02 ± 4.73) and were able to stay longer on the rotarod (at 88 days, 91.1 ± 4.5) than the MRL/MpJ (at start: 45.56 ± 5.03 ; at 88 days, 65.1 ± 5.4 ; Fig. 1a). In both mouse strains, the rotarod performance decreased after SCI (MRL/MpJ, -13.0 ± 4.0 and C57BL/6, -19.0 ± 3.5). Interestingly, the injured MRL/MpJ mice reached their baseline level by the end of 88 days of testing, whereas the performance of the injured C57BL/6 animals was still reduced (23.5 ± 3.9 below their baseline performance at 88 days; Fig. 1a). To eliminate the strain differences in rotarod performance from the recovery curve after SCI, the performance of the injured MRL/MpJ and C57BL/6 mice was normalized to their respective baseline levels (Fig. 1b). There was no difference in the normalized rotarod performance of MRL/MpJ and C57BL/6 mice at 4 days after injury, indicating that both strains were affected equally by the SCI. Interestingly, MRL/MpJ mice recovered rotarod performance over time whereas C57BL/6 did not recover over the 88 days of testing [repeated measures ANOVA: effect of group ($F_{1, 18} = 149.2$, $P < 0.0001$), time ($F_{13, 234} = 5.5$, $P < 0.0001$), interaction group \times

time ($F_{13, 234} = 3.1$, $P < 0.0005$)]. Individual comparisons (Bonferroni post-hoc) between groups indicated that injured MRL/MpJ performed significantly better than injured C57BL/6 at 12, 18, 53, 60, 67, 74 and 88 dpi ($P < 0.002$).

The grid test was used to assess deficits in descending fine motor control after SCI. Intact animals of both mouse strains improved their ability to cross the grid with fewer foot-faults over time (Fig. 1c). However, intact MRL/MpJ animals made significantly more foot-faults through the entire training period (18 days, 2.4 ± 0.5 foot-faults; $p = 0.0025$) than C57BL/6 (18 days, 0.8 ± 0.15 foot-faults). Following SCI, animals from both strains made more foot-faults when crossing the grid: MRL/MpJ 9.5 ± 2.7 and C57BL/6 mice 3.5 ± 1.6 additional foot-faults. The injured MRL/MpJ animals reached their baseline level by 12 dpi, whereas the injured C57BL/6 never recovered back to their baseline level within the testing period of 18 days (Fig. 1c). To account for differences in baseline performance, the number of foot-faults of the injured mice was expressed as a ratio of the baseline (Fig. 1d). Again, we did not find significant differences in the normalized performance on the grid walk of MRL/MpJ and C57BL/6 4 days after the injury, indicating that both strains were impaired similarly by the SCI. MRL/MpJ mice showed a better performance than C57BL/6 on the grid at 12 and 18 days [repeated measures ANOVA: effect of group ($F_{1, 18} = 10.4$, $P < 0.002$), time ($F_{3, 54} = 3.7$, $P < 0.01$), interaction group \times time ($F_{3, 54} = 2.0$, $P > 0.1$); in individual comparisons (Bonferroni post-




Figure 1. Enhanced functional recovery after SCI in MRL/MpJ mice. **a**, The latency to fall off the rotarod is depicted as a function of time for intact (baseline) and injured MRL/MpJ and C57BL/6 mice. In both strains intact mice improved their performance over the course of the 88 days of training, but the C57BL/6 performed better at all time points tested. The injured MRL/MpJ reached their baseline level by the end of the 88 days of testing, whereas the injured C57BL/6 did not. **b**, Rotarod performance of injured mice is expressed as a ratio of baseline performance. Injured MRL/MpJ performed significantly better than injured C57BL/6 at 12, 18, 53, 60, 67, 74 and 88 dpi ($*P < 0.002$). Injured MRL/MpJ significantly improved between 4 dpi and 88 dpi ($\#P < 0.002$), whereas injured C57BL/6 did not improve during that period. **c**, The number of foot-faults made during grid walking is reported as a function of time for intact (baseline) and injured MRL/MpJ and C57BL/6 mice. Both intact strains improved their ability to cross the grid with fewer foot-faults, but intact MRL/MpJ made more foot-faults throughout the entire training period. The injured MRL/MpJ reached their baseline level already by 12 dpi, whereas the injured C57BL/6 still had not reached their baseline level by the end of the testing period at 18 dpi. **d**, Grid walking performance of injured mice is expressed as a ratio to baseline performance. Injured MRL/MpJ performed significantly better than injured C57BL/6 at 12 and 18 dpi ($p < 0.05$). Injured MRL/MpJ had significantly improved between 4 dpi and 12 dpi, 18 dpi ($p < 0.05$), whereas injured C57BL/6 did not improve during that period. **e**, Estimation of bladder fullness is reported as a function of time after SCI in MRL/MpJ and C57BL/6 mice. All MRL/MpJ mice recovered autonomic bladder function by 3 dpi, whereas in C57BL/6 mice, autonomic bladder function did not returned until 6 dpi (Mann Whitney test, p -value = 0.028). Data present mean \pm SEM. * denotes significant difference between MRL/MpJ and C57BL/6 and # denotes significant differences in MRL/MpJ performance between time points (P value: two-way ANOVA, Bonferroni post-hoc analysis). doi:10.1371/journal.pone.0030904.g001

hoc), injured MRL/MpJ performed significantly better than injured C57BL/6 at 12 and 18 dpi, $P < 0.05$].

The gait of the lesioned mice was evaluated by analyzing footprint patterns. When assessing base of support and stride length, we found a trend for the injured MRL/MpJ mice to recover faster than the injured C57BL/6 animals, but the differences were not statistically significant (data not shown).

The bladders of the injured animals were manually expressed twice daily until the mice had recovered autonomic bladder function. At 6 hours post-injury (0 dpi), none of the injured animals showed autonomic bladder function. All MRL/MpJ mice recovered autonomic bladder function by 3 dpi, whereas in C57BL/6 mice, autonomic bladder function did not return until 6 dpi [Mann Whitney test of group difference in Area Under Curve summary statistic of mouse bladder function recovery; p -value = 0.028].

Enhanced regeneration of CST axons in MRL/MpJ mice after SCI

To show that the CST was completely transected by our lesion approach (a 0.5 mm dorsal hemisection), intact MRL/MpJ and intact C57BL/6 mice were injected with BDA. Two weeks later these mice underwent a dorsal hemisection and the CST was assessed at 4 dpi (i.e., 18 days after tracing). In both mouse strains the dorsal CST was BDA-labeled and fully transected. Axons were observed rostral as well as caudal to the injury site, but there were no BDA-labeled fibers in the injury epicenter (Fig. 2 a, b).

To analyze the regeneration of the CST after SCI, injured animals were injected with BDA at 40 or 95 dpi. Irrespective of the time point of BDA tracing, we found that C57BL/6 CST axons had retracted from the lesion site and we observed very few or no fibers caudal to the lesion (Fig. 2c, e, g). In contrast, MRL/MpJ CST fibers were present at the lesion site as well as caudal to the injury. Moreover, in some cases, CST axons crossed through the lesion site (Fig. 2d, f, h). At both time points, MRL/MpJ mice displayed significantly more fibers at and caudal to the lesion site compared to C57BL/6 mice [Fig. 2i, j; two-way ANOVA revealed significant effect of group (54 dpi: $F_{1, 10} = 6.8$, $P < 0.05$; 109 dpi: $F_{1, 18} = 11.2$, $P < 0.005$)]. Individual comparisons (Bonferroni post-hoc) between groups indicated that injured MRL/MpJ had significantly more regenerating fibers at 0.5 mm rostral to the lesion site ($P < 0.02$): 54 dpi: $19.3 \pm 9.9\%$ for MRL/MpJ versus $1.3 \pm 1.3\%$ for C57BL/6; 109 dpi: $19.5 \pm 9.2\%$ for MRL/MpJ versus $3.2 \pm 1.5\%$ for C57BL/6.

In both mouse strains, no significant difference in fiber quantification was found between 54 dpi and 109 dpi, demonstrating that the regenerated fibers were stable and did not retract.

Reduced astrocytic response and micro-cavity formation in MRL/MpJ mice after SCI

At 54 dpi the dorsal surface of the injury site in the C57BL/6 mice was convex, bulging and filled with densely packed GFAP-positive astrocytes. Numerous GFAP-positive astrocytes were delineating the injury site forming a glial scar (Fig. 3a, c). In MRL/MpJ mice, the dorsal surface of the injury site was concave and contained GFAP-negative cells surrounded by a few GFAP-positive astrocytes. The incision site itself was no longer visible in MRL/MpJ spinal cord (Fig. 3b, d). Furthermore, the lesion epicenter of C57BL/6 mice contained 10 times more micro-cysts than the lesion site of MRL/MpJ mice (211.9 ± 23.3 micro-cavities/ mm^3 vs. 26.1 ± 2.7 micro-cavities/ mm^3 ; Student's t -test, $p < 0.002$; Fig. 3.e, f, g).

At 109 dpi the tissue looked similar to 54 dpi in C57BL/6 mice: the injury site in the C57BL/6 mice was still visible, filled with GFAP-positive astrocytes and micro-cavities (Fig. 3h). In MRL/MpJ mice, the dorsal surface of the injury site was flat and fewer GFAP-positive astrocytes were present (Fig. 3i) when compared to the C57BL/6 injury site. The lesion site could be located because of the higher cell division at the injury site compared to the surrounding spinal cord tissue.

Cell proliferation is different in the intact and injured spinal cord in MRL/MpJ mice

Previous studies have identified progenitor cells throughout the intact and injured rodent spinal cord [23,28,29,30]. Therefore, we examined whether differences between C57BL/6 and MRL/MpJ endogenous spinal cord progenitor cell proliferation could account for the enhanced healing properties of MRL/MpJ mice.

Quantification of BrdU-positive cells in intact spinal cord 1 day after six days of BrdU application revealed a higher level of proliferation in MRL/MpJ mice ($p < 0.05$; Fig. 4b,c). Survival of the progeny of dividing progenitor cells was assessed by evaluating BrdU-positive cells 4 weeks after the last BrdU injection and comparing the number of labeled cells with the number obtained at 1 day after the last injection. The total number of surviving BrdU-positive cells after 4 weeks in MRL/MpJ spinal cord was not significantly different from C57BL/6 mice ($p > 0.05$; Fig. 4c). The cell fate of the BrdU-positive cells 4 weeks post-injection was also assessed in the intact spinal cord. As reported previously for the rat intact spinal cord [23], there was no sign of ongoing neurogenesis detected in MRL/MpJ or C57BL/6 intact spinal cords. In both strains, the majority of the BrdU-positive cells was immature glia (co-labeled with NG2) or mature astrocytes (co-labeled with S100b/GFAP). No significant differences were detected between MRL/MpJ and C57BL/6 (data not shown).

As described previously [28,29,30], a substantial increase in cellular proliferation occurs after SCI in and around the injury site (Fig. 4d-f). We injected BrdU 2 h after SCI and once daily for 6 dpi. When compared to intact mice, the number of proliferating cells at the site of injury at 1 dpi was 23.5-fold higher for C57BL/6 mice and only 9.6 times higher for MRL/MpJ mice ($p < 0.05$), showing that MRL/MpJ injured cord contained 1.5 times fewer BrdU-labeled nuclei than C57BL/6 lesioned cord. The number of BrdU-labeled nuclei in MRL/MpJ mice was still 1.5 times lower at 54 dpi (Fig. 4 e, f), whereas no significant difference was found at 109 dpi.

Apoptotic cells were detected at 1 dpi using TUNEL labeling [31]. Numerous TUNEL-positive cells exhibiting typical fragmented and condensed nucleus were detected at the injury epicenter in both mouse strains (MRL/MpJ: 3292 ± 569 apoptotic cells/ mm^3 ; C57BL/6 3645 ± 631 apoptotic cells/ mm^3). Similarly, Fluoro-jade staining specifically detecting neuronal cell death [32] revealed no differences between MRL/MpJ (2499 ± 101 Fluoro-jade-positive cells/ mm^3) and C57BL/6 mice (2590 ± 348 degenerating neurons/ mm^3) at 1 dpi at the injury site.

Reduced astrocytic and increased microglial differentiation of proliferating cells in MRL/MpJ injured spinal cord

Since it has been suggested that the astroglial scar is in part produced by proliferating precursor cells differentiating into astrocytes post-injury [29,33,34,35], the cell fate of the dividing cells after SCI was examined in both strains.

In intact mice, differentiation of the surviving BrdU-positive cells was examined in the spinal cord 4 weeks after the last BrdU




Figure 2. Enhanced regeneration of corticospinal tract (CST) axons in MRL/MpJ mice after SCI. **a, b**, Sagittal sections of BDA-labeled CST axons in C57BL/6 (**a**) and MRL/MpJ (**b**) mice. Two weeks after tracing, dorsal hemisections were performed. The CST was analyzed at 4 dpi (= 18 days after tracing). In both mouse strains, axons are visible rostral and caudal from the injury site. No BDA-labeled fibers were found at the injury site, confirming that the CST was completely transected. **c, d**, Sagittal sections of BDA-labeled CST axons in injured C57BL/6 (**c**) and MRL/MpJ (**d**) mice at 54 dpi. Here, BDA tracing was performed right after SCI. C57BL/6 CST axons retracted from the lesion (arrowhead in **c**). In contrast, some MRL/MpJ CST fibers crossed through the lesion site (arrowhead in **d**). **e, f**, Montage of sagittal sections of BDA-labeled CST axons in C57BL/6 (**e**) and MRL/MpJ (**f**) mice at 109 dpi. Higher magnifications are shown in **g** (from boxed area in **e**) and **h** (from boxed area in **f**). We found no BDA-positive fibers below the injury site in C57BL/6 spinal cord (**e, g**), in contrast to MRL/MpJ mice (**f, h**). **i, j**, Data represent percentage of fibers and are reported as a function of the distance from the lesion at 54 dpi (**i**) and 109 dpi (**j**). MRL/MpJ mice exhibited significantly more regenerating axons at 0.5 mm caudal from the lesion site. Rostral end of the spinal cord is to the left. The arrows point at the injury site. Asterisks denote significant differences between MRL/MpJ and C57BL/6, $P < 0.02$ (two-way ANOVA, Bonferroni Post-hoc). Scale bar, 250 μm (**a-d**); 300 μm (**e, f**); 100 μm (**g, h**). doi:10.1371/journal.pone.0030904.g002

injection by means of confocal microscopy and immunofluorescent double labeling for BrdU with lineage-specific markers (neuronal markers NeuN and TUJ1, glial progenitor marker NG2, astrocyte markers GFAP and S100b, microglia marker OX-42). No significant differences were found between MRL/MpJ and C57BL/6 mice (data not shown). In accordance with previous publications [23,28], no evidence of neurogenesis was found. Many proliferating cells were oligodendroglial progenitor cells (>40%), approximately 5% were astrocytes and fewer than 1% were microglia.

We then assessed the phenotype of BrdU-positive cells in injured mice. At 54 dpi, no neurogenesis occurred in either of the

strains and most of the surviving proliferating cells exhibited a glial phenotype (Fig. 5). The proportions of BrdU-positive cells colabeled with NG2 ($9.7 \pm 2.1\%$ vs $4.7 \pm 2.0\%$), S100b ($4.0 \pm 2.1\%$ vs $2.9 \pm 1.4\%$) and OX-42 ($2.0 \pm 1.4\%$ vs $1.6 \pm 1.4\%$) in C57BL/6 versus MRL/MpJ mice were not significantly different (Fig. 5s). Nevertheless, BrdU+/GFAP+ cells were significantly higher in C57BL/6 mice ($22.5 \pm 0.5\%$) than in MRL/MpJ animals ($16.1 \pm 0.8\%$; $p < 0.05$; Fig. 5s). When we assessed double-labeled cells (absolute numbers) per volume, we found that C57BL/6 mice had almost 3 times more NG2+/BrdU+ cells (Fig. 5g-l) and 2 times more GFAP+/BrdU+ cells (Fig. 5a-f) than MRL/MpJ mice




Figure 3. Reduced astrocytic response and micro-cavity formation in MRL/MpJ mice after SCI. **a, b**, Sagittal sections of the lesion epicenter at 54 dpi labeled with GFAP (red) and counterstained with DAPI (blue) in C57BL/6 (**a**) and MRL/MpJ (**b**) mice. Higher magnifications are shown in **c** (from boxed area in **a**) and **d** (from boxed area in **b**). The dorsal surface of the injury site in the C57BL/6 mice bulged out and was filled with GFAP-positive astrocytes. In white and gray matter, numerous GFAP-positive astrocytes delineated the incision site (**a, c**). In MRL/MpJ mice, the dorsal surface of the injury site was concave and contained GFAP-negative cells surrounded by a few GFAP-positive astrocytes. The incision site was not visible any more (**b, d**). **e, f**, Sagittal sections of the lesion epicenter at 54 dpi stained for GFAP in C57BL/6 (**e**) and MRL/MpJ (**f**) mice. Numerous micro-cavities (arrowheads) are present at the injury site (arrows) in C57BL/6 mice (**e**) compared to none or few in MRL/MpJ mice (**f**). **g**, Bars represent the number of micro-cavities per cm^3 at the injury epicenter at 54 dpi. C57BL/6 injured spinal cord developed significantly more micro-cavities than MRL/MpJ cord. **h, i**, Sagittal sections of the lesion epicenter at 109 dpi labeled with GFAP (red) and BrdU (green) in C57BL/6 (**h**) and MRL/MpJ (**i**) mice. The injury site of the C57BL/6 mice was filled with GFAP-positive astrocytes and micro-cavities were present (**h**). The injury site in the MRL/MpJ mice was not visible any more and could only be located by the presence of BrdU+ cells. The dorsal surface of the injury site was flat and few GFAP-positive astrocytes were present. (**i**). Asterisks denote significant difference between MRL/MpJ and C57BL/6, $P < 0.002$ (Student's t-test). Scale bar, 250 μm (**a, b, h, i**); 140 μm (**c, d**); 125 μm (**e, f**). doi:10.1371/journal.pone.0030904.g003

(Fig. 5u; $p < 0.05$), but there was no significant difference between the number of OX-42+/BrdU+ cells. At 109 dpi, the phenotype of BrdU-labeled cells was similar to 54 dpi with C57BL/6 mice, showing still more GFAP+/BrdU+ cells than MRL/MpJ mice (1167.8 ± 172.3 vs 660.9 ± 151.5 ; $p < 0.05$; Fig. 5t, v). But interestingly, at 109 dpi, OX-42+/BrdU+ cells were absent in C57/BL6 mice, whereas they represented $2.7 \pm 0.9\%$ of the MRL/MpJ BrdU-labeled cells ($p < 0.05$; Fig. 5n-r, t, v).

Gene expression profiling of the MRL/MpJ and C57BL/6 injured spinal cord

To assess the molecular events occurring in the MRL/MpJ spinal cord after injury and to reveal putative candidate genes responsible for the enhanced spinal cord repair, we used microarray technology. To exclude as many genes as possible

that are changed by SCI in general, and to find genes that are strictly differentially regulated in MRL/MpJ mice, we used different criteria when analyzing the gene chips. We used “loose” criteria (dChip1.3 fold change > 1.2 OR Drop method confidence = 50%) to reveal differentially expressed genes in C57BL/6 spinal cord 4 days after dorsal hemisection and found 1538 genes. We applied “strict” criteria (dChip1.3 fold change > 1.2 AND Drop method confidence = 95%) to find genes differentially expressed in MRL/MpJ spinal cord 4 days after dorsal hemisection and found 745 genes. Of these genes, 272 are exclusively regulated in MRL/MpJ injured spinal cord (Fig. 6a; complete data set available at http://genechip.salk.edu/rawdata/Thuret_MRL.zip). We also compared gene expression in the intact spinal cord of MRL/MpJ and C57BL/6 mice using the “strict” criteria and found 54 genes to be differentially expressed.




Figure 4. Higher cell proliferation in intact spinal cord but lower increase in cell proliferation after SCI in MRL/MpJ mice. **a, b**, Immunohistochemical staining for BrdU (arrowheads) on cross sections at the mid-thoracic level of intact spinal cord in C57BL/6 (**a**) and MRL/MpJ (**b**) mice 24 h after the last of 6 daily BrdU injections. **c**, Graphs show the amount of BrdU-labeled nuclei per mm³ in the intact spinal cord at the thoracic level 24 h and 4 weeks after the last BrdU injection. MRL/MpJ mice showed a 1.5× higher level of cell proliferation than C57BL/6. Cell survival was assessed at 4 weeks and there was no significant difference between the two strains. **d**, Number of BrdU-labeled nuclei per mm³ in the injured spinal cord 1, 54 and 109 dpi. BrdU was injected after injury and for the 6 following days. MRL/MpJ spinal cord showed less cell proliferation at 1 and 54 dpi. **e, f**, Sagittal sections of the lesion epicenter at 54 dpi stained for BrdU in C57BL/6 (**e**) and MRL/MpJ (**f**) mice. Asterisks denote significant difference between MRL/MpJ and C57BL/6, $P < 0.05$ (Student's *t*-test). Scale bar, 260 μ m. doi:10.1371/journal.pone.0030904.g004

None of these genes was among the 272 genes that were differentially expressed in MRL/MpJ injured spinal cord exclusively.

We focused our interest on the genes that were exclusively differentially expressed in MRL/MpJ injured spinal cord and classified the 103 upregulated genes (Fig. 6b) and the 169 downregulated genes by biological function (Fig. 6c). More than a quarter of these genes are to date Expressed Sequence Tags (ESTs) or have an unknown function. Following SCI, MRL/MpJ mice appear to upregulate mainly genes implicated in repair mechanisms: 10% of the upregulated genes are involved in cytoskeleton reorganization, 16% take part in protein and ribosome biosynthesis and 24% participate in cell cycle, DNA replication, lipid metabolism, angiogenesis, glycolysis or cell adhesion. Genes involved in inflammatory processes (6%) are also upregulated upon SCI in MRL/MpJ mice. Among the 169 downregulated genes, 24% are involved in cell proliferation and differentiation, 12% in cation/ion transport and 12% take part in the signal transduction cascade. Genes participating in the protein ubiquitination process are also downregulated (10%), suggesting a diminished cellular degradation upon SCI in MRL/MpJ mice. Table 1 shows the 10 most up- and down-regulated genes in MRL/MpJ injured spinal cord of which expression levels have also been verified by Q-PCR. In particular, the interferon activated gene 202B (*Ifi202b*)-encoding p202b [36]- is increased 35.66 fold in the injured MRL/MpJ spinal cord and is unchanged in C57BL/6 (Table 1). The second highest fold change difference ($\times 7.59$) is the allograft inflammatory factor 1 gene (*Aif1*). This gene is an interferon (IFN)-gamma-inducible Ca²⁺-binding EF-hand protein.

The identification of candidate genes that complement our histological findings reveals potential molecular mechanisms associated with the enhanced spinal cord healing ability of MRL/MpJ mice.

Discussion

The aim of this work was to assess whether MRL/MpJ mice show enhanced spinal cord repair upon injury. We performed a dorsal spinal cord hemisection and used the C57BL/6 mouse as a control strain. We show in this study that MRL/MpJ mice recover faster than C57BL/6 mice in several behavioral tests. This recovery parallels the enhanced regeneration of CST axons in MRL/MpJ mice. Our data suggest that these axons have a facilitated passage across the injury site because of the reduced astrocytic response and diminished micro-cavity formation in MRL/MpJ mice. The reduced astrocytic response is probably due to reduced cell proliferation post-injury and reduced astrocytic differentiation of the proliferating cells. In addition, we observed an increased microglial differentiation in MRL/MpJ mice, suggesting a possible role of the inflammatory response in the MRL/MpJ spinal cord repair mechanisms. Finally, to evaluate the molecular basis of enhanced spinal cord repair, we examined the gene expression changes after SCI in MRL/MpJ and C57BL/6 mice. The microarray data complement our histological findings and unveil a transcriptional profile that reflects the more efficient spinal cord repair in MRL/MpJ mice

Locomotor recovery and axonal regeneration

The dorsal hemisection destroys a portion of supraspinal input to the lumbar spinal cord and produces major, but incomplete, loss of hindlimb function. Moreover, there is a slight possibility for a minority of CST fibers to not have been fully transected in our model. The limited recovery of C57BL/6 animals in motor tasks




Figure 5. Reduced astrocytic differentiation in MRL/MpJ injured spinal cord. Sagittal sections of the lesion epicenter at 54 dpi (a–l) and 109 dpi (m–r) labeled for BrdU (green) and lineage markers (red): GFAP (a–f), NG2 (g–l), OX-42 (m–r) in C57BL/6 (a–c, g–i, m–o) and MRL/MpJ (d–f, j–l, p–r) mice. Higher magnifications of cells marked by the arrowheads are shown in boxed inserts. s–v, Graphs represent the quantification of BrdU-labeled cells stained for a specific marker at 54 dpi (s, u) and 109 dpi (t, v) shown as percentage of all BrdU-labeled cells (s, t) and as absolute number of co-stained BrdU-labeled nuclei per mm³ (u, v). At 54 dpi, C57BL/6 mice showed more NG2/BrdU- and GFAP/BrdU-positive cells than MRL/MpJ mice. At 109 dpi, C57BL/6 mice had still more GFAP/BrdU-expressing cells than MRL/MpJ mice; however, OX-42/BrdU-positive cells were only found in MRL/MpJ spinal cord (2.7±0.9%). Asterisks denote significant difference between MRL/MpJ and C57BL/6, P<0.05 (Student's t-test). Scale bar, 100 μm (a–i); 50 μm (p–r); 50 μm for boxed area (a–i); 25 μm for boxed area (p–r). doi:10.1371/journal.pone.0030904.g005

may be attributed to distal rearrangements of spared descending fibers. Recently, it has been demonstrated that local plasticity after SCI creates new circuits between descending CST fibers and cervico-lumbar propriospinal neurons [37]. In MRL/MpJ mice, the recovery of locomotor function was significantly improved. Only in the MRL/MpJ mice did we find CST fiber growth caudal to the injury site, suggesting an important role for regrowing fibers in behavioral recovery. CST axonal regeneration, similar to what we observed in MRL/MpJ mice, has been associated with functional recovery after treatment and in transgenic mice [8,38,39,40,41,42]. It is also possible that the inherent plasticity of the injured spinal cord for creating new circuitries [37] is enhanced in MRL/MpJ mice. We assume that MRL/MpJ CST axons grow because of a more permissive environment at the injury site: (i) we observed fewer micro-cavities providing a better environment for tissue repair and axonal regeneration [43,44] and (ii) we found fewer astrocytes at the injury site, which have been shown to form a physical barrier preventing axonal growth [7]. Thus, we suggest that MRL/MpJ mice have a more permissive environment for axonal regeneration,

with a reduced physical barrier and probably a diminished production of growth-inhibitory molecules.

Astrocytic response

For both MRL/MpJ and C57BL/6 mice, the majority of proliferating cells at the injury site differentiated into astrocytes. However, C57BL/6 mice had twice as many newborn astrocytes than MRL/MpJ. Astrocytes are the major contributor to the growth-inhibitory scar after an injury, which is one of the obstacles for successful regeneration. It has been suggested that part of the astroglial scar formed after injury is attributable to newly generated astrocytes and not to activation or migration of resident astrocytes [33]. MRL/MpJ injured spinal cord contains fewer newborn astrocytes, probably due to (i) a diminished increase in cell proliferation at the injury site and (ii) a lower astrocytic differentiation of the proliferating cells. X-irradiation treatment eliminates rapidly dividing cells after SCI, suppresses glial scar formation [9,45] and improves functional recovery [9,46]. Taken together, these data suggest that limiting cell proliferation upon




Figure 6. Gene expression profiling of the MRL/MpJ and C57BL/6 injured spinal cord. **a**, Using loose criteria (dChip1.3 fold change > 1.2 OR Drop method confidence = 50%), 1538 genes were found to be differentially expressed in C57BL/6 spinal cord 4 days after hemisection. Using strict criteria (dChip1.3 fold change > 1.2 AND Drop method confidence = 95%), 745 differentially expressed genes were found in MRL/MpJ spinal cord 4 days after hemisection, and 272 of these genes were exclusive for the MRL/MpJ injured spinal cord. **b**, Classification by biological function of genes up-regulated exclusively in MRL/MpJ injured spinal cord. **c**, Classification by biological function of genes down-regulated exclusively in MRL/MpJ injured spinal cord.
doi:10.1371/journal.pone.0030904.g006

SCI might be beneficial to reducing astrogliosis and the formation of scar tissue.

Inflammatory response

Our data from the gene profiling analysis at 4 dpi suggest an amplified inflammatory response in injured MRL/MpJ spinal cord. Among the genes exclusively differentially expressed in MRL/MpJ injured spinal cord, the second highest fold change difference ($\times 7.59$) is the allograft inflammatory factor 1 gene (*Aif1*; Table 1). This gene encodes an interferon (IFN)-gamma-inducible Ca²⁺-binding EF-hand protein. In the brain, a subset of microglial cells constitutively expresses AIF-1 [47]. Increased numbers of

AIF-1-immunoreactive macrophages/microglial cells were observed in brain tumors and ischemia [48] as well as after SCI [49].

The spinal cord tissue analysis at 109 dpi showed a higher rate of microglia differentiation and/or macrophage recruitment in MRL/MpJ mice, indicating that the immune response might be sustained for the entire repair process. Immune system activity has traditionally been considered harmful for recovery after SCI [48,50,51,52]. However, some studies have shown the potential beneficial effect of a strong inflammatory response. For example, Franzen and colleagues [53] have transplanted macrophages into the injured adult rat spinal cord and suggest that macrophages may exert beneficial effects by degrading myelin products, which

inhibit axonal re-growth, and by promoting a permissive extracellular matrix. Moreover, Rapalino and colleagues [54] observed partial recovery of paraplegic rats after implantation of stimulated homologous macrophages. Lastly, Foote and Blake-more [55] have shown that inflammation stimulates remyelination in areas of chronic demyelination. The increased immune response seen in the gene profiling analysis might be due to a more permeable blood-brain-barrier (BBB) because of reduced gliosis. Furthermore, MRL/MpJ mice contain elevated numbers of macrophage progenitor cells circulating in their blood [56], which could possibly pass the more permeable BBB, invade the injury site and proliferate.

Interestingly the Transforming Growth Factor beta is a key regulator in immune responses [57] and its mRNA is upregulated 1.9-fold more in MRL/MpJ injured spinal cord. Injecting TGFβ1 was shown to stimulate astrocytes [58]; however, a recent study found an exacerbated astroglial reaction in TGFβ1^{-/-} mice [59]. The spinally injured MRL/MpJ mice in our studies showed a reduced astroglial reaction and decreased micro-cavity formation. Importantly, TGFβ1 was shown to promote the survival of various CNS neurons *in vitro*, including motoneurons [60]. Additionally, TGFβ1 prevents neuronal degeneration caused by hypoxic or excitotoxic injury *in vitro* and rescues hippocampal CA1 neurons from death after transient ischemia *in vivo* [61,62]. Furthermore, anti-TGFβ1 treatment following SCI exacerbates secondary damage by increasing the size of cavities in the injured tissue [63], and treatment of SCI rats with TGFβ1 reduces lesion volume [64].

The inbred MRL/MpJ strain has a mild autoimmune disorder and is used as a background strain for mutating the Fas gene leading to lupus erythematosus (SLE). The severity of autoimmunity in these mutant mice is strongly affected by the genetic background in which they are placed [65]. The inbred MRL/MpJ strain background creates a severe lupus disease, and even Fas-sufficient MRL/MpJ mice suffer from a mild-late-onset SLE [66]. Interestingly, recent evidence suggests that autoimmunity is an endogenous response to CNS injury and that it can be beneficial for repair [67,68]. Further studies showed that passive transfer of T-cells specific to myelin basic protein reduces neuronal loss after SCI and promotes recovery in rats [69,70,71]. Together these data suggest that part of MRL/MpJ functional recovery might be linked to their mild autoimmune disorder.

Brain repair versus spinal cord repair

Hampton and colleagues [72] studied the brain response to injury in MRL/MpJ mice. They did not observe enhanced axonal regeneration after cutting the dopaminergic projection from the substantia nigra to the striatum. Neither did they see a reduced scar after a stab lesion to the cortex. The only common observation between this and the present study was the enhanced and prolonged microglial activity.

In contrast to what we found in the spinal cord, they observed a higher increase in cell proliferation in the cortex after injury. Interestingly, in MRL/MpJ spinal cord we found a dramatic +35.88-fold change for a gene whose over-expression in mammalian cells inhibits cell proliferation: the interferon activated gene 202B (*Ifi202b*) encoding the p202b protein. This inhibition of proliferation might be correlated with the binding and inhibition of the activity of several transcription factors by p202, such as c-Fos, c-Jun, AP2, E2F-1, E2F-4, MyoD, myogenin, and NF-κB p50 and p65 [73,74,75].

In unlesioned MRL/MpJ mice, we observed a lower cell proliferation in the hippocampus than in C57BL/6 animals [76], whereas in the uninjured MRL/MpJ spinal cord we observed a

higher cell proliferation. Proliferation in the brain and the spinal cord are differently regulated in intact tissue, therefore it might be also the case following injury. In general, spinal cord and brain seem to react conversely regarding cell proliferation: running increases cell proliferation in the hippocampus but decreases proliferation in the spinal cord of C57BL/6 (our unpublished data).

Another disparity between brain and spinal cord involves the inflammatory response. The acute inflammatory response to traumatic injury is significantly greater in the spinal cord than in the cerebral cortex [77]. Overall, we suspect that the disparity between MRL/MpJ brain and spinal cord repair might be due to a combination of intrinsic differences in cell proliferation and inflammatory response.

Hemisection versus Contusion

More recently, Kostyk and colleagues [78] have assessed the spinal cord regenerative abilities at T9 of MRL/MpJ versus C57/Bl6 mice. They also reported a robust axon growth within the lesion at 28 dpi in MRL/MpJ mice. However, the extent of locomotor recovery was reported to be impaired in the MRL/MpJ mice by 42 dpi. They further described evidence of ongoing degeneration both within and around the lesion site at 42 dpi. Interestingly, Kostyk and colleagues have used a contusion model using rapid displacement of an impounder on the exposed spinal cord following a dorsal laminectomy producing a contusion of moderate severity. These data are consistent with our initial pilot contusion data using the IH-impactor device at 50Kdynes (data not shown), which lead to impaired locomotor recovery in MRL/MpJ mice by 43 dpi. This is in contrast to the present study using a dorsal hemisection model where axonal growth was consistent with functional recovery. It is important to highlight that to inflict a contusion injury using an impounder, it is necessary to make a very large laminectomy. This is in contrast with making a very small laminectomy for a dorsal hemisection. Interestingly, postmortem dissection of our contused mouse samples (data not shown) uncovered a cartilaginous overgrowth within the large laminectomy region inducing a fusion between the remaining neighboring vertebrae leading to extreme spinal column distortion. This distortion possibly explains the poor motor performance of this contusion group. In contrast, such cartilaginous overgrowth was never observed with small laminectomies associated with the dorsal hemisection procedures.

Moreover, a contusion injury is a crude injury as opposed to a micro-scissors hemisection, which is a sharp injury. Interestingly, it has been shown that regeneration of the ear in MRL/MpJ mice depends on the type of wound trauma, where a crude injury (punch) does not heal as well as a sharp injury (clinical biopsy) [79]. Indeed, Rajnoch and colleagues [79] have previously shown that in crude thumb-punched MRL/MpJ ears, an increase in wound area diameter was still observed at the day-28 time point. By contrast, biopsy-punched MRL/MpJ ears showed an 85% wound closure over the same period.

The observations of this study, together with Hampton and colleagues [72] as well as Kostyk and colleagues [78] findings suggest that the occurrence of an enhanced regenerative ability is not exclusively dictated by genetic influences, but is also highly dependent on local cellular interactions and injury type.

Validation of the gene expression profiling after SCI

To help us understand the events occurring in the MRL/MpJ spinal cord after injury, we analyzed gene expression changes after SCI in both strains and compared the results to compile a list of genes differentially expressed exclusively in MRL/MpJ injured

spinal cord. Since it is known that genes are differentially regulated in different strains of mice or rats [80,81], we only focused on genes that are specifically expressed in injured MRL/MpJ spinal cord. We have evidences that the MRL/MpJ differentially expressed genes identified in this screen are potentially implicated in spinal cord repair. First, we observed, in both strains some genes that have previously been shown to be differentially regulated after SCI. For example, both mouse strains show expression changes in genes coding for proteins that influence apoptosis: Caspase 3 is upregulated and Caspase 7 is downregulated, as observed previously [25,82]. These studies also found Bax and Bak1 to be upregulated upon SCI, as we have in the present study. For both injured strains, genes coding for cathepsin proteases are upregulated (cathepsins B, C, D, L and S), as previously reported [25,83,84,85]. These data validate that our method is useful for identifying candidate genes that contribute to differences in spinal cord repair between MRL/MpJ and C57BL/6 mice. Second, we found that some of the genes differentially expressed in MRL/MpJ injured spinal cord are located on the quantitative trait loci QTLs that control ear healing in MRL/MpJ mice [16,19,21]. These studies found linkage on chromosome 7. Interestingly, some of the genes differentially expressed in injured MRL/MpJ spinal cord (e.g., genes coding for the mitochondrial uncoupling protein 2 and TGF β 1) are located in or near the loci on chromosome 7. Additionally, Masinde et al. [21] found linkage on chromosome 1, where *Ifi202b*, another of our candidate genes, is located. We found that some genes differentially expressed in the MRL/MpJ healing ear are also present on our gene list. For example we observed that *Decorin* is less up-regulated whereas *DEAD/H* and *Proteasome (prosome, macropain)* are more up-regulated in MRL/MpJ, as previously reported in a different lesion model [21]. We also found that *integrin beta2* and *secretory granule proteoglycan* are more up-regulated in MRL/MpJ upon injury, as shown previously [20]. Since rapid wound healing in MRL/MpJ mice is a genetically controlled quantitative trait [15,19], we expected that the soft tissue regeneration QTLs and genes found in studies on ear regeneration in MRL/MpJ mice would overlap with the genes discovered in this study. The fact that some of the differentially expressed genes are located within the QTL regions or have already been identified provides another validation of our screen. Third, our microarray data complement our histological findings. Indeed, the general tendency is the up-regulation of genes involved in repair mechanisms. Moreover, genes involved in lowering cell

proliferation (e.g., *Ifi202b*) and increasing the immune response (e.g., *Aif-1*) are up-regulated in the injured MRL/MpJ spinal cord.

We recognize that this study may underestimate the number of genes involved in MRL/MpJ spinal cord healing because (i) we examined only one time point and some changes in the expression may occur at an earlier or later stage of the repair process, (ii) we used only one strain of mice for control, and (iii) we collected only the lesion epicenter and additional genes might be differently regulated rostral and/or caudal to the lesion. Moreover, it would be interesting in future studies to extract RNA from specific cell types to identify the particular cells responsible for these significant gene expression changes. However, the genes identified here may play a role in the repair processes following SCI and further characterization of these candidates might elucidate some molecular mechanisms of spinal cord repair.

Conclusion and perspectives

This study shows that the MRL/MpJ mice are able to recover faster and better after spinal cord dorsal hemisection than C57BL/6 mice. Our data suggest that a sustained immune response and decreased astrocytic activity are likely to be part of a complex recovery course. Although our data are not able to explain the detailed mechanisms of such a recovery, they do demonstrate that the repair process after SCI is multifaceted. Many pathways are involved, all of which need to be considered and each of which needs to work at an optimal “level” to result in behavioral recovery.

Supporting Information

Table S1 Primer Sequences for Q-PCR. (DOCX)

Acknowledgments

The authors wish to thank J. Brad Aimone for the analysis of the GeneChip Arrays, Lisa Schnell and Martin Schwab for discussion, and Mary Lynn Gage for editing the manuscript.

Author Contributions

Conceived and designed the experiments: ST FHG. Performed the experiments: ST MT LLH. Analyzed the data: ST MT FHG. Wrote the paper: ST MT FHG.

References

- Thuret S, Moon LD, Gage FH (2006) Therapeutic interventions after spinal cord injury. *Nat Rev Neurosci* 7: 628–643.
- Chen MS, Huber AB, van der Haar ME, Frank M, Schnell L, et al. (2000) Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1. *Nature* 403: 434–439.
- Fitch MT, Doller C, Combs CK, Landreth GE, Silver J (1999) Cellular and molecular mechanisms of glial scarring and progressive cavitation: in vivo and in vitro analysis of inflammation-induced secondary injury after CNS trauma. *J Neurosci* 19: 8182–8198.
- Davies SJ, Fitch MT, Memberg SP, Hall AK, Raisman G, et al. (1997) Regeneration of adult axons in white matter tracts of the central nervous system. *Nature* 390: 680–683.
- Neumann S, Woolf CJ (1999) Regeneration of dorsal column fibers into and beyond the lesion site following adult spinal cord injury. *Neuron* 23: 83–91.
- Stichel CC, Muller HW (1998) Experimental strategies to promote axonal regeneration after traumatic central nervous system injury. *Prog Neurobiol* 56: 119–148.
- Fawcett JW, Asher RA (1999) The glial scar and central nervous system repair. *Brain Res Bull* 49: 377–391.
- Bradbury EJ, Moon LD, Popat RJ, King VR, Bennett GS, et al. (2002) Chondroitinase ABC promotes functional recovery after spinal cord injury. *Nature* 416: 636–640.
- Ridet JL, Penechal P, Belcram M, Giraudeau B, Chastang C, et al. (2000) Effects of spinal cord X-irradiation on the recovery of paraplegic rats. *Exp Neurol* 161: 1–14.
- Ferretti P, Zhang F, O'Neill P (2003) Changes in spinal cord regenerative ability through phylogenesis and development: lessons to be learnt. *Dev Dyn* 226: 245–256.
- Clark LD, Clark RK, Heber-Katz E (1998) A new murine model for mammalian wound repair and regeneration. *Clin Immunol Immunopathol* 88: 35–45.
- Leferovich JM, Bedelbaeva K, Samulewicz S, Zhang XM, Zwas D, et al. (2001) Heart regeneration in adult MRL mice. *Proc Natl Acad Sci U S A* 98: 9830–9835.
- Chadwick RB, Bu L, Yu H, Hu Y, Wergedal JE, et al. (2007) Digit tip regrowth and differential gene expression in MRL/MpJ, DBA/2, and C57BL/6 mice. *Wound Repair Regen* 15: 275–284.
- Gourevitch DL, Clark L, Bedelbaeva K, Leferovich J, Heber-Katz E (2009) Dynamic changes after murine digit amputation: The MRL mouse digit shows waves of tissue remodeling, growth, and apoptosis. *Wound Repair and Regeneration* 17: 447–455.
- Li X, Gu W, Masinde G, Hamilton-Ulland M, Xu S, et al. (2001) Genetic control of the rate of wound healing in mice. *Heredity* 86: 668–674.
- Blankenhorn EP, Troutman S, Clark LD, Zhang XM, Chen P, et al. (2003) Sexually dimorphic genes regulate healing and regeneration in MRL mice. *Mamm Genome* 14: 250–260.
- Heber-Katz E, Chen P, Clark L, Zhang XM, Troutman S, et al. (2004) Regeneration in MRL mice: further genetic loci controlling the ear hole closure trait using MRL and M.m. Castaneus mice. *Wound Repair Regen* 12: 384–392.

18. Masinde GL, Li X, Gu W, Davidson H, Mohan S, et al. (2001) Identification of wound healing/regeneration quantitative trait loci (QTL) at multiple time points that explain seventy percent of variance in (MRL/MpJ and SJL/J) mice F2 population. *Genome Res* 11: 2027–2033.
19. McBrearty BA, Clark LD, Zhang XM, Blankenhorn EP, Heber-Katz E (1998) Genetic analysis of a mammalian wound-healing trait. *Proc Natl Acad Sci U S A* 95: 11792–11797.
20. Li X, Mohan S, Gu W, Baylink DJ (2001) Analysis of gene expression in the wound repair/regeneration process. *Mamm Genome* 12: 52–59.
21. Masinde G, Li X, Baylink DJ, Nguyen B, Mohan S (2005) Isolation of wound healing/regeneration genes using restrictive fragment display-PCR in MRL/MPJ and C57BL/6 mice. *Biochem Biophys Res Commun* 330: 117–122.
22. Thallmair M, Metz GAS, Z'Graggen WJ, Raineteau O, Kartje GL, et al. (1998) Neurite growth inhibitors restrict plasticity and functional recovery following corticospinal tract lesions. *Nature Neuroscience* 1: 124–131.
23. Horner PJ, Power AE, Kempermann G, Kuhn HG, Palmer TD, et al. (2000) Proliferation and differentiation of progenitor cells throughout the intact adult rat spinal cord. *Journal of Neuroscience* 20: 2218–2228.
24. Whiteside G, Coughon N, Hunt SP, Munglani R (1998) An improved method for detection of apoptosis in tissue sections and cell culture, using the TUNEL technique combined with Hoechst stain. *Brain Research Protocols* 2: 160–164.
25. Aimone JB, Leasure JL, Perreau VM, Thallmair M (2004) Spatial and temporal gene expression profiling of the contused rat spinal cord. *Exp Neurol* 189: 204–221.
26. Li C, Wong WH (2001) Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. *Proc Natl Acad Sci U S A* 98: 31–36.
27. Aimone JB, Gage FH (2004) Unbiased characterization of high-density oligonucleotide microarrays using probe-level statistics. *J Neurosci Methods* 135: 27–33.
28. Horkey LL, Galimi F, Gage FH, Horner PJ (2006) Fate of endogenous stem/progenitor cells following spinal cord injury. *J Comp Neurol* 498: 525–538.
29. Johanson CB, Momma S, Clarke DL, Risling M, Lendahl U, et al. (1999) Identification of a neural stem cell in the adult mammalian central nervous system. *Cell* 96: 25–34.
30. Yamamoto S, Yamamoto N, Kitamura T, Nakamura K, Nakafuku M (2001) Proliferation of parenchymal neural progenitors in response to injury in the adult rat spinal cord. *Experimental Neurology* 172: 115–127.
31. Whiteside G, Coughon N, Hunt SP, Munglani R (1998) An improved method for detection of apoptosis in tissue sections and cell culture, using the TUNEL technique combined with Hoechst stain. *Brain Res Brain Res Protoc* 2: 160–164.
32. Schmued LC, Stowers CC, Scallet AC, Xu L (2005) Fluoro-Jade C results in ultra high resolution and contrast labeling of degenerating neurons. *Brain Res* 1035: 24–31.
33. Kernie SG, Erwin TM, Parada LF (2001) Brain remodeling due to neuronal and astrocytic proliferation after controlled cortical injury in mice. *J Neurosci Res* 66: 317–326.
34. Okada S, Nakamura M, Mikami Y, Shimazaki T, Mihara M, et al. (2004) Blockade of interleukin-6 receptor suppresses reactive astrogliosis and ameliorates functional recovery in experimental spinal cord injury. *J Neurosci Res* 76: 265–276.
35. Takahashi M, Arai Y, Kurosawa H, Sueyoshi N, Shirai S (2003) Ependymal cell reactions in spinal cord segments after compression injury in adult rat. *J Neuropathol Exp Neurol* 62: 185–194.
36. Wang H, Chatterjee G, Meyer JJ, Liu CJ, Manjunath NA, et al. (1999) Characteristics of three homologous 202 genes (Ifi202a, Ifi202b, and Ifi202c) from the murine interferon-activatable gene 200 cluster. *Genomics* 60: 281–294.
37. Bareyre FM, Kerschensteiner M, Raineteau O, Mettenleiter TC, Weinmann O, et al. (2004) The injured spinal cord spontaneously forms a new intraspinal circuit in adult rats. *Nat Neurosci* 7: 269–277.
38. Demjen D, Klusmann S, Kleber S, Zuliani C, Stieltjes B, et al. (2004) Neutralization of CD95 ligand promotes regeneration and functional recovery after spinal cord injury. *Nat Med* 10: 389–395.
39. Goldshmit Y, Galea MP, Wise G, Bartlett PF, Turnley AM (2004) Axonal regeneration and lack of astrocytic gliosis in EphA4-deficient mice. *J Neurosci* 24: 10064–10073.
40. Menet V, Prieto M, Privat A, Gimenez y Ribotta M (2003) Axonal plasticity and functional recovery after spinal cord injury in mice deficient in both glial fibrillary acidic protein and vimentin genes. *Proc Natl Acad Sci U S A* 100: 8999–9004.
41. Li S, Liu BP, Budel S, Li M, Ji B, et al. (2004) Blockade of Nogo-66, myelin-associated glycoprotein, and oligodendrocyte myelin glycoprotein by soluble Nogo-66 receptor promotes axonal sprouting and recovery after spinal injury. *J Neurosci* 24: 10511–10520.
42. Schwab ME (2004) Nogo and axon regeneration. *Curr Opin Neurobiol* 14: 118–124.
43. Ramer LM, Au E, Richter MW, Liu J, Tetzlaff W, et al. (2004) Peripheral olfactory ensheathing cells reduce scar and cavity formation and promote regeneration after spinal cord injury. *J Comp Neurol* 473: 1–15.
44. Ohta M, Suzuki Y, Noda T, Ejiri Y, Dezawa M, et al. (2004) Bone marrow stromal cells infused into the cerebrospinal fluid promote functional recovery of the injured rat spinal cord with reduced cavity formation. *Exp Neurol* 187: 266–278.
45. Zhang SX, Geddes JW, Owens JL, Holmberg EG (2005) X-irradiation reduces lesion scarring at the contusion site of adult rat spinal cord. *Histol Histopathol* 20: 519–530.
46. Zeman RJ, Feng Y, Peng H, Visintainer PF, Moorthy CR, et al. (2001) X-irradiation of the contusion site improves locomotor and histological outcomes in spinal cord-injured rats. *Exp Neurol* 172: 228–234.
47. Mittelbronn M, Dietz K, Schlusener HJ, Meyermann R (2001) Local distribution of microglia in the normal adult human central nervous system differs by up to one order of magnitude. *Acta Neuropathol* 101: 249–255.
48. Popovich PG, Wei P, Stokes BT (1997) Cellular inflammatory response after spinal cord injury in Sprague-Dawley and Lewis rats. *J Comp Neurol* 377: 443–464.
49. Schwab JM, Frei E, Klusman I, Schnell L, Schwab ME, et al. (2001) AIF-1 expression defines a proliferating and alert microglial/macrophage phenotype following spinal cord injury in rats. *J Neuroimmunol* 119: 214–222.
50. Popovich PG, Guan Z, Wei P, Huitinga I, van Rooijen N, et al. (1999) Depletion of hematogenous macrophages promotes partial hindlimb recovery and neuroanatomical repair after experimental spinal cord injury. *Exp Neurol* 158: 351–365.
51. Blight AR (1992) Macrophages and inflammatory damage in spinal cord injury. *J Neurotrauma* 9 Suppl 1: S83–91.
52. Jones TB, Ankeny DP, Guan Z, McGaughy V, Fisher LC, et al. (2004) Passive or active immunization with myelin basic protein impairs neurological function and exacerbates neuropathology after spinal cord injury in rats. *J Neurosci* 24: 3752–3761.
53. Franzen R, Schoenen J, Leprince P, Joosten E, Moonen G, et al. (1998) Effects of macrophage transplantation in the injured adult rat spinal cord: a combined immunocytochemical and biochemical study. *J Neurosci Res* 51: 316–327.
54. Rapalino O, Lazarov-Spiegler O, Agranov E, Velan GJ, Yoles E, et al. (1998) Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats. *Nat Med* 4: 814–821.
55. Foote AK, Blakemore WF (2005) Inflammation stimulates remyelination in areas of chronic demyelination. *Brain* 128: 528–539.
56. Davis TA, Lennon G (2005) Mice with a regenerative wound healing capacity and an SLE autoimmune phenotype contain elevated numbers of circulating and marrow-derived macrophage progenitor cells. *Blood Cells Mol Dis* 34: 17–25.
57. Letterio JJ, Roberts AB (1997) TGF- β : A Critical Modulator of Immune Cell Function. *Clinical Immunology and Immunopathology* 84: 244–250.
58. Logan A, Berry M, Gonzalez AM, Frautschy SA, Sporn MB, et al. (1994) Effects of transforming growth factor beta 1 on scar production in the injured central nervous system of the rat. *Eur J Neurosci* 6: 355–363.
59. Makwana M, Jones LL, Cuthill D, Heuer H, Bohatschek M, et al. (2007) Endogenous transforming growth factor beta 1 suppresses inflammation and promotes survival in adult CNS. *J Neurosci* 27: 11201–11213.
60. Martinou JC, Le Van Thai A, Valette A, Weber MJ (1990) Transforming growth factor beta 1 is a potent survival factor for rat embryo motoneurons in culture. *Brain Res Dev Brain Res* 52: 175–181.
61. Henrich-Noack P, Prehn JH, Kriegstein J (1996) TGF- β 1 protects hippocampal neurons against degeneration caused by transient global ischemia. Dose-response relationship and potential neuroprotective mechanisms. *Stroke* 27: 1609–1614; discussion 1615.
62. Prehn JH, Backhaus C, Kriegstein J (1993) Transforming growth factor-beta 1 prevents glutamate neurotoxicity in rat neocortical cultures and protects mouse neocortex from ischemic injury in vivo. *J Cereb Blood Flow Metab* 13: 521–525.
63. King VR, Phillips JB, Brown RA, Priestley JV (2004) The effects of treatment with antibodies to transforming growth factor beta1 and beta2 following spinal cord damage in the adult rat. *Neuroscience* 126: 173–183.
64. Tyor WR, Avgeropoulos N, Ohlandt G, Hogan EL (2002) Treatment of spinal cord impact injury in the rat with transforming growth factor-beta. *J Neurol Sci* 200: 33–41.
65. Vidal S, Kono DH, Theofilopoulos AN (1998) Loci predisposing to autoimmunity in MRL-Fas lpr and C57BL/6-Faslpr mice. *J Clin Invest* 101: 696–702.
66. Theofilopoulos AN, Dixon FJ (1985) Murine models of systemic lupus erythematosus. *Adv Immunol* 37: 269–390.
67. Schwartz M, Kipnis J (2001) Protective autoimmunity: regulation and prospects for vaccination after brain and spinal cord injuries. *Trends Mol Med* 7: 252–258.
68. Yoles E, Hauben E, Palgi O, Agranov E, Gothilf A, et al. (2001) Protective autoimmunity is a physiological response to CNS trauma. *J Neurosci* 21: 3740–3748.
69. Hauben E, Butovsky O, Nevo U, Yoles E, Moalem G, et al. (2000) Passive or active immunization with myelin basic protein promotes recovery from spinal cord contusion. *J Neurosci* 20: 6421–6430.
70. Hauben E, Agranov E, Gothilf A, Nevo U, Cohen A, et al. (2001) Posttraumatic therapeutic vaccination with modified myelin self-antigen prevents complete paralysis while avoiding autoimmune disease. *J Clin Invest* 108: 591–599.
71. Ibarra A, Hauben E, Butovsky O, Schwartz M (2004) The therapeutic window after spinal cord injury can accommodate T cell-based vaccination and methylprednisolone in rats. *Eur J Neurosci* 19: 2984–2990.
72. Hampton DW, Seitz A, Chen P, Heber-Katz E, Fawcett JW (2004) Altered CNS response to injury in the MRL/MpJ mouse. *Neuroscience* 127: 821–832.

73. Min W, Ghosh S, Lengyel P (1996) The interferon-inducible p202 protein as a modulator of transcription: inhibition of NF-kappa B, c-Fos, and c-Jun activities. *Mol Cell Biol* 16: 359–368.
74. Choubey D, Gutterman JU (1997) Inhibition of E2F-4/DP-1-stimulated transcription by p202. *Oncogene* 15: 291–301.
75. Datta B, Min W, Burma S, Lengyel P (1998) Increase in p202 expression during skeletal muscle differentiation: inhibition of MyoD protein expression and activity by p202. *Mol Cell Biol* 18: 1074–1083.
76. Thuret S, Toni N, Aigner S, Yeo GW, Gage FH (2009) Hippocampus-dependent learning is associated with adult neurogenesis in MRL/MpJ mice. *Hippocampus* 19: 658–669.
77. Schnell L, Fearn S, Schwab ME, Perry VH, Anthony DC (1999) Cytokine-induced acute inflammation in the brain and spinal cord. *J Neuropathol Exp Neurol* 58: 245–254.
78. Kostyk SK, Popovich PG, Stokes BT, Wei P, Jakeman LB (2008) Robust axonal growth and a blunted macrophage response are associated with impaired functional recovery after spinal cord injury in the MRL/MpJ mouse. *Neuroscience* 156: 498–514.
79. Rajnoch C, Ferguson S, Metcalfe AD, Herrick SE, Willis HS, et al. (2003) Regeneration of the ear after wounding in different mouse strains is dependent on the severity of wound trauma. *Dev Dyn* 226: 388–397.
80. Dimou L, Schnell L, Montani L, Duncan C, Simonen M, et al. (2006) Nogo-A-deficient mice reveal strain-dependent differences in axonal regeneration. *J Neurosci* 26: 5591–5603.
81. Schmitt C, Miranpuri GS, Dhodda VK, Isaacson J, Vemuganti R, et al. (2006) Changes in spinal cord injury-induced gene expression in rat are strain-dependent. *Spine J* 6: 113–119.
82. Citron BA, Arnold PM, Sebastian C, Qin F, Malladi S, et al. (2000) Rapid upregulation of caspase-3 in rat spinal cord after injury: mRNA, protein, and cellular localization correlates with apoptotic cell death. *Exp Neurol* 166: 213–226.
83. Ellis RC, Earnhardt JN, Hayes RL, Wang KK, Anderson DK (2004) Cathepsin B mRNA and protein expression following contusion spinal cord injury in rats. *J Neurochem* 88: 689–697.
84. Ellis RC, O'Steen WA, Hayes RL, Nick HS, Wang KK, et al. (2005) Cellular localization and enzymatic activity of cathepsin B after spinal cord injury in the rat. *Exp Neurol* 193: 19–28.
85. Hashimoto M, Koda M, Ino H, Yoshinaga K, Murata A, et al. (2005) Gene expression profiling of cathepsin D, metallothioneins-1 and -2, osteopontin, and tenascin-C in a mouse spinal cord injury model by cDNA microarray analysis. *Acta Neuropathol* 109: 165–180.